Warning: The NCBI web site requires JavaScript to function. more...
Aggrecanolysis and in vitro matrix degradation in the immature bovine meniscus: mechanisms and functional implications.
Wilson CG, Vanderploeg EJ, Zuo F, Sandy JD, Levenston ME.
Arthritis Res Ther. 2009;11(6):R173. Epub 2009 Nov 17.
Related citations
Interleukin-1alpha treatment of meniscal explants stimulates the production and release of aggrecanase-generated, GAG-substituted aggrecan products and also the release of pre-formed, aggrecanase-generated G1 and m-calpain-generated G1-G2.
Lemke AK, Sandy JD, Voigt H, Dreier R, Lee JH, Grodzinsky AJ, Mentlein R, Fay J, Schünke M, Kurz B.
Cell Tissue Res. 2010 Apr;340(1):179-88. Epub 2010 Mar 9.
Release of hyaluronan and hyaladherins (aggrecan G1 domain and link proteins) from articular cartilage exposed to ADAMTS-4 (aggrecanase 1) or ADAMTS-5 (aggrecanase 2).
Chockalingam PS, Zeng W, Morris EA, Flannery CR.
Arthritis Rheum. 2004 Sep;50(9):2839-48.
Nitric oxide enhances aggrecan degradation by aggrecanase in response to TNF-alpha but not IL-1beta treatment at a post-transcriptional level in bovine cartilage explants.
Stevens AL, Wheeler CA, Tannenbaum SR, Grodzinsky AJ.
Osteoarthritis Cartilage. 2008 Apr;16(4):489-97. Epub 2007 Oct 10.
Selective and non-selective metalloproteinase inhibitors reduce IL-1-induced cartilage degradation and loss of mechanical properties.
Wilson CG, Palmer AW, Zuo F, Eugui E, Wilson S, Mackenzie R, Sandy JD, Levenston ME.
Matrix Biol. 2007 May;26(4):259-68. Epub 2006 Nov 11.
Tumor necrosis factor alpha-dependent aggrecan cleavage and release of glycosaminoglycans in the meniscus is mediated by nitrous oxide-independent aggrecanase activity in vitro.
Voigt H, Lemke AK, Mentlein R, Schünke M, Kurz B.
Arthritis Res Ther. 2009;11(5):R141. Epub 2009 Sep 24.
Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro.
Little CB, Flannery CR, Hughes CE, Mort JS, Roughley PJ, Dent C, Caterson B.
Biochem J. 1999 Nov 15;344 Pt 1:61-8.
Mannosamine inhibits aggrecanase-mediated changes in the physical properties and biochemical composition of articular cartilage.
Patwari P, Kurz B, Sandy JD, Grodzinsky AJ.
Arch Biochem Biophys. 2000 Feb 1;374(1):79-85.
Fibroblast growth factor 2 inhibits induction of aggrecanase activity in human articular cartilage.
Sawaji Y, Hynes J, Vincent T, Saklatvala J.
Arthritis Rheum. 2008 Nov;58(11):3498-509.
Chondrocytes and meniscal fibrochondrocytes differentially process aggrecan during de novo extracellular matrix assembly.
Wilson CG, Nishimuta JF, Levenston ME.
Tissue Eng Part A. 2009 Jul;15(7):1513-22.
Inhibition of cartilage degradation and changes in physical properties induced by IL-1beta and retinoic acid using matrix metalloproteinase inhibitors.
Bonassar LJ, Sandy JD, Lark MW, Plaas AH, Frank EH, Grodzinsky AJ.
Arch Biochem Biophys. 1997 Aug 15;344(2):404-12.
Analysis of ADAMTS4 and MT4-MMP indicates that both are involved in aggrecanolysis in interleukin-1-treated bovine cartilage.
Patwari P, Gao G, Lee JH, Grodzinsky AJ, Sandy JD.
Osteoarthritis Cartilage. 2005 Apr;13(4):269-77.
Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro.
Hughes CE, Caterson B, Fosang AJ, Roughley PJ, Mort JS.
Biochem J. 1995 Feb 1;305 ( Pt 3):799-804.
Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments.
Struglics A, Larsson S, Pratta MA, Kumar S, Lark MW, Lohmander LS.
Osteoarthritis Cartilage. 2006 Feb;14(2):101-13. Epub 2005 Sep 26.
Aggrecanase- and matrix metalloproteinase-mediated aggrecan degradation is associated with different molecular characteristics of aggrecan and separated in time ex vivo.
Madsen SH, Sumer EU, Bay-Jensen AC, Sondergaard BC, Qvist P, Karsdal MA.
Biomarkers. 2010 May;15(3):266-76.
MMPs are less efficient than ADAMTS5 in cleaving aggrecan core protein.
Durigova M, Nagase H, Mort JS, Roughley PJ.
Matrix Biol. 2011 Mar;30(2):145-53. Epub 2010 Nov 3.
Mechanisms involved in cartilage proteoglycan catabolism.
Caterson B, Flannery CR, Hughes CE, Little CB.
Matrix Biol. 2000 Aug;19(4):333-44. Review.
Evidence of a novel aggrecan-degrading activity in cartilage: Studies of mice deficient in both ADAMTS-4 and ADAMTS-5.
Rogerson FM, Stanton H, East CJ, Golub SB, Tutolo L, Farmer PJ, Fosang AJ.
Arthritis Rheum. 2008 Jun;58(6):1664-73.
Matrix metalloproteinase 17 is necessary for cartilage aggrecan degradation in an inflammatory environment.
Clements KM, Flannelly JK, Tart J, Brockbank SM, Wardale J, Freeth J, Parker AE, Newham P.
Ann Rheum Dis. 2011 Apr;70(4):683-9. Epub 2011 Jan 7.
Detection of aggrecanase- and MMP-generated catabolic neoepitopes in the rat iodoacetate model of cartilage degeneration.
Janusz MJ, Little CB, King LE, Hookfin EB, Brown KK, Heitmeyer SA, Caterson B, Poole AR, Taiwo YO.
Osteoarthritis Cartilage. 2004 Sep;12(9):720-8.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on